U.S. FDA approves Merck's lung cancer drug as first-line treatment
Merck & Co Inc on Monday said the U.S. Food and Drug Administration has approved its immunotherapy Keytruda for use in certain previously untreated lung cancer patients, making it the only approved first-line treatment. The drug has been approved for treating metastatic non-small cell lung cancer patients with high-levels of a protein known for suppressing the immune system called PD-L1.
from Biotech News
0 Comments